Market Pulse
Daily · Oct 7, 2026 · data.go.kr + ECOS
KOSPI
6,803.90
-137.49 (-1.98%)
KOSDAQ
898.43
-21.49 (-2.34%)
KOSPI 200
1,073.63
-22.20 (-2.03%)
USD/KRW
1,338.50
185750KOSPI·Aug 24, 2026
Limited earnings improvement, but pipeline development on track
Mirae Asset Securities published a company analysis report on Chong Kun Dang Pharmaceutical Corp. (185750) titled "Limited earnings improvement, but pipeline development on track".
Summary
Covers Chong Kun Dang Pharmaceutical Corp. (185750).
Covered stock
More on 185750
Atrial fibrillation asset newly reflected in pipeline valueMirae Asset Securities · Feb 27, 2026Earnings Stable; R&D Also Steadily in ProgressKB Securities · Nov 04, 2025Focus on the potential of HDAC6 inhibitorMirae Asset Securities · Aug 05, 2025Focus on clinical trial plans for CKD-510Mirae Asset Securities · Feb 04, 2025